Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rani Therapeutics Holdings (RANI – Research Report) and Amgen (AMGN – Research Report).
Rani Therapeutics Holdings (RANI)
BTIG analyst Julian Harrison maintained a Buy rating on Rani Therapeutics Holdings yesterday and set a price target of $24.00. The company’s shares closed last Wednesday at $1.91, close to its 52-week low of $1.85.
According to TipRanks.com, Harrison is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $20.25 average price target, which is a 933.2% upside from current levels. In a report issued on October 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
Amgen (AMGN)
Mizuho Securities analyst Salim Syed assigned a Hold rating to Amgen on October 31 and set a price target of $223.00. The company’s shares closed last Wednesday at $260.84.
According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $281.78 average price target, representing a 10.0% upside. In a report issued on October 16, Morgan Stanley also initiated coverage with a Hold rating on the stock with a $300.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RANI:
- Rani Therapeutics announces preclinical data on RaniPill platform
- Rani announces oral delivery of monoclonal antibody via high-capacity pill
- Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
- Rani Therapeutics initiates Phase 1 study of RT-111
